Analgesic from Xgene Pharmaceutical Reduces Pain and Opioid Use in Post-Surgical Trial
Analgesic from Xgene Pharmaceutical Reduces Pain and Opioid Use in Post-Surgical Trial Xgene Pharmaceutical has revealed further findings from a positive, multi-center, placebo-controlled, dose-ranging Phase 2b study (registration number: NCT06017999) evaluating the safety and efficacy of its XG005 oral tablet…
OS Therapies Completes $6 Million Private Placement
OS Therapies Completes $6 Million Private Placement OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company specializing in cancer immunotherapy and antibody-drug conjugates, today announced the successful completion of a private placement financing, raising approximately $6 million in gross proceeds.…
Cardiovascular Update: Cadrenal’s 2024 Progress on Tecarfarin for LVAD
Cardiovascular Update: Cadrenal’s 2024 Progress on Tecarfarin for LVAD Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) today provided a summary of its key milestones for 2024, along with its strategic plan to advance tecarfarin, an investigational anticoagulant therapy. The company aims to…
Verastem Unveils Critical FDA Review of Avutometinib-Defactinib for Ovarian Cancer
Verastem Unveils Critical FDA Review of Avutometinib-Defactinib for Ovarian Cancer Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company dedicated to advancing new cancer treatments, has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA)…
Inogen Gets FDA 510(k) Clearance for SIMEOX 200 Device
Inogen Gets FDA 510(k) Clearance for SIMEOX 200 Device Inogen, Inc. (Nasdaq: INGN), a medical technology company specializing in innovative respiratory products for homecare use, today announced it has received FDA 510(k) clearance for the SIMEOX 200 Airway Clearance Device.…
RenovoRx Expands IP Portfolio for Novel Drug-Delivery Platform
RenovoRx Expands IP Portfolio for Novel Drug-Delivery Platform RenovoRx, Inc. (Nasdaq: RNXT), a life sciences company focused on developing targeted oncology therapies and commercializing the FDA-cleared RenovoCath® delivery system, today emphasized its robust intellectual property (IP) portfolio. The company is…
Series E and E1 Warrant Exercises Secure $16.3 Million for Delcath Systems
Series E and E1 Warrant Exercises Secure $16.3 Million for Delcath Systems Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company dedicated to treating primary and metastatic liver cancers, announced today the exercise of 1.7 million Series E and Series…
Marinus Pharmaceuticals to Be Acquired by Immedica
Marinus Pharmaceuticals to Be Acquired by Immedica Immedica Pharma AB, a global leader in rare diseases, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a company dedicated to enhancing the lives of patients with seizure disorders, have announced a merger agreement. Under…
CEL-SCI Prices $5 Million Public Offering
CEL-SCI Prices $5 Million Public Offering CEL-SCI Corporation (NYSE American: CVM), a clinical-stage immunotherapy company focused on cancer treatments, today announced the pricing of a public offering of 16,130,000 shares of its common stock or pre-funded warrants (in lieu of…
Superior HealthPlan Marks 25th Anniversary with $25,000 Grant to NAMI El Paso
Superior HealthPlan Marks 25th Anniversary with $25,000 Grant to NAMI El Paso Superior HealthPlan, a prominent managed care organization in Texas and a subsidiary of Centene Corporation (NYSE: CNC), announced a $25,000 grant to National Alliance on Mental Illness (NAMI)…
HCA Healthcare Appoints Wendy Warren as SVP & Chief Ethics Officer
HCA Healthcare Appoints Wendy Warren as SVP & Chief Ethics Officer HCA Healthcare, Inc. (NYSE: HCA), one of the nation’s leading healthcare providers, has announced the appointment of Wendy Warren as senior vice president and chief ethics and compliance officer,…
Opdivo Qvantig™ FDA Approved for Subcutaneous Use in Adult Solid Tumor Indications
Opdivo Qvantig™ FDA Approved for Subcutaneous Use in Adult Solid Tumor Indications Bristol Myers Squibb (NYSE: BMY) recently announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use. This combination…